Long-term effects of octreotide on markers of bone metabolism in acromegaly: Evidence of increased serum parathormone concentrations

Journal of Endocrinological Investigation

Volumn 20, Issue 8, 1997, Pages 434-438

  Legovini, P ^a   De Menis, E ^a   Breda, F ^a   Billeci, D ^a   Carteri, A ^a   Pavan, P ^a   Conte, N ^a  

^a OSPEDALE CA FONCELLO   (Italy)

Author keywords

Acromegaly; Bone; Bone markers; Octreotide; Osteocalcin; Parathormone

Indexed keywords

ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; CALCIUM; COLLAGEN TYPE 1; GROWTH HORMONE; HYDROXYPROLINE; OCTREOTIDE; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE; SOMATOMEDIN C;

ACROMEGALY; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE METABOLISM; BONE TURNOVER; CALCIUM ABSORPTION; CALCIUM BLOOD LEVEL; CALCIUM HOMEOSTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYDROXYPROLINE URINE LEVEL; LONG TERM CARE; MALABSORPTION; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE URINE LEVEL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030778777     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03347998     Document Type: Article

References (26)

1. Inzucchi S.E., Bobbins J. Effects of growth hormone on human bone biology. J. Clin. Endocrinol. Metab. 79: 691, 1994.
2. Ezzat S., Melmed S., Endres D., Eyre D., Singer F. Biochemical assessment of bone formation and resorption in acromegaly. J. Clin. Endocrinol. Metab. 76: 1452, 1993.
3. Takamoto S., Tsuchiya H., Onishi T., Morimoto S., Imanaka S., Mori S., Seino Y., Uozumi T., Kumahara Y. Changes in calcium homeostasis in acromegaly treated by pituitary adenomectomy. J. Clin. Endocrinol. Metab. 61: 7, 1985.
4. Johansen J.S., Pederson S.A., Jorgensen J.O.L., Riis BJ., Christiansen C., Christiansen J.S., Skakkebaek Ne. Effects of growth hormone (GH) on plasma bone GIa protein in GH-deficient adults. J. Clin. Endocrinol. Metab. 70: 916, 1990.
5. Marazuela M., Astigarraga B., Tabuenca M.J., Estrada J., Marin F., Lucas T. Serum bone GLA protein as a marker of bone turnover in acromegaly. Calcif. Tissue Int. 52: 419, 1993.
6. Eskildsen P.C., Lund B., Sorensen O.H., Lund B., Bishop J.E., Norman A.W. Acromegaly and vitamin D metabolism: effect of bromocriptine treatment. J. Clin. Endocrinol. Metab. 49: 484, 1979.
7. Legovini P., De Menis E., Doroldi C., Carteri A., Billeci D., Roiter I., Breda F., Conte N. Parathormone levels during treatment of acromegaly with octreotide: one-year follow-up. Curr. Ther. Res. 53: 360, 1993.
8. Kanis J., Yates A. Measuring serum calcium. Br. Med. J. 290: 728, 1985.
9. Sigurdsson G., Nunziata V., Reiner M., Nadarajah A., Joplin GF. Calcium absorption and excretion in the gut in acromegaly. Clin. Endocrinol. 2: 187, 1973.
10. Halse J, Haugen H.N. Calcium and phosphate metabolism in acromegaly. Acta Endocrinol. 94: 459, 1980.
11. Lund B., Eskildsen P.C., Lund B., Norman A.W., Sorensen O.H. Calcium and vitamin D metabolism in acromegaly. Acta Endocrinol. 96: 444, 1981.
12. Spanos E., Barrett D., Maclntyre I., Pike J.W., Safilian E.F., Haussler M.R. Effect of growth hormone on vitamin D metabolism. Nature 273: 246, 1978.
13. Spencer E.M., Tobiassen O. The mechanism of the action of growth hormone on vitamin D metabolism in the rat. Endocrinology 108: 1064, 1981.
14. Corvilain J., Abramow M. Some effects of human growth hormone on renal hemodynamics and on tubular phosphate transport in man. J. Clin. Invest. 41: 1230, 1962.
15. Camanni F., Massara F., Losana O., Molinatti G.M. Increased renal tubular reabsorption of phosphate in acromegaly. J. Clin. Endocrinol. Metab. 28: 999, 1968.
16. Canalis E., Lian J.B. Effects of bone associated growth factors on DNA, collagen and osteocalcin synthesis in cultured fetal rat calvariae. Bone 9: 243, 1980.
17. Skjodt H., Gallangher J.A., Berensford J.N. Vitamin D metabolites regulate osteocalcin synthesis and proliferation of human bone cells in vitro. J. Endocrinol. 67:391, 1985.
18. De la Piedra C., Carbo E., Larranaga J., Castro N., Horcajada C., Rapado A., Herrera Pombo J.L. Correlation among plasma osteocalcin, growth hormone, and somatomedin C in acromegaly. Calcif. Tissue Int. 43: 44, 1988.
19. Piovesan A., Terzolo M., Reimondo G., Pia A., Codegone G., Osella G., Boccuzzi A., Paccotti P., Angeli A. Biochemical markers of bone and collagen turnover in acromegaly or Cushing's syndrome. Horm. Metab. Res. 26:234, 1994.
20. Fredstorp L., Pernow Y., Wener S. The short and long-term effects of octreotide on calcium homeostasis in patients with acromegaly. Clin. Endocrinol. 39: 331, 1993.
21. Deftos L.J., Lorenzi M., Bohanon N., Tsalakian E., Schneider V., Gerich J.E. Somatostatin does not suppress plasma parathyroid hormone. J. Clin. Endocrinol. Metab. 43:205, 1976.
22. Scholz D., Schwille P.O. Somatostatin and intestinal calcium absorption in man. Metabolism 27 (Suppl. 1): 1349, 1978.
23. Hargis G.K., Williams G.A., Reynolds A., Chertow B.S., Kukreja S.C., Bowser N., Henderson W.J. Effect of somatostatin on parathyroid hormone and calcitonin secretion. Endocrinology 102: 745, 1978.
24. Botana M.A., Castillo L., Pesquera C., Freijanes J., Amado J.A., Gonzalez-Macias J. Lack of effect of octreotide on parathyroid hormone levels and urinary excretion of epidermal growth factor. Horm. Metab. Res. 25:37, 1993.
25. Terzolo M., Piovesan A., Osella., Pia A., Reimondo G., Pozzi C., Raucci C., Torta M., Paccotti P., Angeli A. Serum levels of bone GLA protein (osteocalcin, BGP) and carboxyterminal propeptide of type I Procollagen (PICP) in acromegaly: effects of long-term octreotide treatment. Calcif. Tissue Int. 52: 188, 1993.
26. Kotzman H., Bernecker P., Hubsh P., Pietschmann P., Woloszczuk W., Svoboda T., Geyer G., Luger A. Bone mineral density and parameters of bone metabolism in patients with acromegaly. J. Bone Miner. Res. 8: 459, 1993.